W. Aaron Pruett
W. Aaron Pruett is drug product process engineer, Novavax.
Articles
Impact of Manufacturing-Scale Freeze-Thaw Conditions on a mAb Solution
February 1st 2017The objective of this study was to assess the impact of manufacturing-scale, freeze-thaw conditions on aggregation and subvisible particle formation of a monoclonal antibody solution (mAb-A; IgG1) using a small-scale model.
Latest Updated Articles
Published: September 11th 2024 | Updated: September 18th 2024
CPHI Pharma Award Finalists Announced for 2024
Published: March 27th 2024 | Updated: June 28th 2024
AbbVie Acquires Landos Biopharma and Gets Full FDA Nod for ADC Product
Published: October 28th 2024 | Updated: November 21st 2024
Discovery to Commercialization: The Right Partnerships are Key to Streamlined Drug Development
Published: November 15th 2024 | Updated: November 21st 2024
Solving Challenges with AAV Aggregate Analysis Using a Novel Size Exclusion Particle to Determine CQAs
Published: October 28th 2024 | Updated: November 21st 2024
Cell-based phenotypic screening with Incucyte® Live-Cell Analysis Systems
Published: October 22nd 2024 | Updated: November 21st 2024
Optimizing cGMP Facility Design Space with a Hybrid Approach
